A new breed of da Vinci® stapling compatible with
the da Vinci Xi and X surgical systems
Intuitive Surgical, Inc. (Nasdaq:ISRG), the pioneer and a
global technology leader in robotic-assisted, minimally invasive
surgery, today announced that the U.S. Food and Drug
Administration granted clearance for the company’s fully
wristed, 60mm stapler.
SureForm 60™, a single-patient use 60mm stapler, offers 120
degrees of fully wristed articulation – an industry first. Surgeons
control SureForm 60 through the da Vinci surgeon console, creating
an immediate connection between clinical decision-making and
instrument action. Combining da Vinci’s tremor filtration with
SureForm 60’s tip stability and 120 degrees of articulation in all
directions may help provide surgeons with precise stapler
manipulation and placement.
SureForm 60 uses SmartFire™ technology—integrated software that
optimizes stapler and staple line performance. SmartFire measures
tissue compression before and during staple firing, making
automatic adjustments to the firing process as staples are formed
and the transection is made. SmartFire makes more than 1,000
measurements per second, helping to ensure a more consistent staple
line, while helping prevent tissue damage, across a range of tissue
thicknesses.
“Intuitive continues our minimally invasive innovation with our
60mm stapler, rooted in extensive research and development and an
understanding of surgeons’ needs,” said Sal Brogna, Intuitive
executive vice president and chief operating officer.
SureForm 60 has general, thoracic, gynecologic, urologic, and
pediatric indications. It is compatible with the da Vinci Xi
and X surgical systems. The SureForm 60 extends the da Vinci
stapling portfolio to cover all required staple line lengths. It
expands and evolves Intuitive’s da Vinci stapling portfolio, which
includes 30 and 45mm stapler instruments.
About Intuitive Surgical, Inc.
Intuitive Surgical, Inc. (Nasdaq:ISRG), headquartered in
Sunnyvale, Calif., is the pioneer and a global technology leader in
robotic-assisted, minimally invasive surgery. Intuitive develops,
manufactures and markets the da Vinci surgical system. The
company strives to make surgery more effective, less invasive and
easier on surgeons, patients and their families.
About the da Vinci Surgical
System
There are several models of the da Vinci surgical
system. The da Vinci surgical systems are designed
to help surgeons perform minimally invasive surgery. Da Vinci
systems offer surgeons high-definition 3D vision, a magnified view,
and robotic and computer assistance. They use specialized
instrumentation, including a miniaturized surgical camera and
wristed instruments (i.e., scissors, scalpels and forceps) that are
designed to help with precise dissection and reconstruction deep
inside the body.
© 2018 Intuitive Surgical, Inc. All rights
reserved. Intuitive Surgical®, da Vinci®, da
Vinci S®, da Vinci® Si™, da Vinci Xi®, da
Vinci X®, OnSite® and EndoWrist® are trademarks or
registered trademarks of Intuitive Surgical, Inc.
For more information, please visit the company's web site
at www.intuitivesurgical.com.
Important Safety Information
For Important Safety Information, indications for use, risks,
full cautions and warnings, please refer to
http://www.davincisurgery.com/safety and
www.intuitivesurgical.com/safety.
Forward-Looking Statements
This press release contains forward-looking statements,
including statements regarding the flexible robotics platform as a
safe and feasible approach to sample lung tissue, the ability of
platform application in the lungs to enable early lung cancer
diagnoses, the strong safety profile of the platform, and enabling
physicians to start care plans for patients earlier and offer
curative treatments. These forward-looking statements are
necessarily estimates reflecting the best judgment of our
management and involve a number of risks and uncertainties that
could cause actual results to differ materially from those
suggested by the forward-looking statements. These forward-looking
statements should, therefore, be considered in light of various
important factors, including, but not limited to, the following:
the impact of global and regional economic and credit market
conditions on healthcare spending; healthcare reform legislation
in the United States and its impact on hospital spending,
reimbursement and fees levied on certain medical device revenues;
changes in hospital admissions and actions by payers to limit or
manage surgical procedures; the timing and success of product
development and market acceptance of developed products; the
results of any collaborations, in-licensing arrangements, joint
ventures, strategic alliances or partnerships; procedure counts;
regulatory approvals, clearances and restrictions or any dispute
that may occur with any regulatory body; guidelines and
recommendations in the healthcare and patient communities;
intellectual property positions and litigation; competition in the
medical device industry and in the specific markets of surgery in
which we operate; unanticipated manufacturing disruptions or the
inability to meet demand for products; the results of legal
proceedings to which we are or may become a party; product
liability and other litigation claims; adverse publicity regarding
the Company and the safety of our products and adequacy of
training; our ability to expand into foreign markets; and other
risk factors under the heading “Risk Factors” in our report on Form
10-K for the year ended December 31, 2016, as updated by our
other filings with the Securities and Exchange Commission.
Statements using words such as “estimates,” “projects,” “believes,”
“anticipates,” “plans,” “expects,” “intends,” “may,” “will,”
“could,” “should,” “would,” “targeted” and similar words and
expressions are intended to identify forward-looking statements.
You are cautioned not to place undue reliance on these
forward-looking statements, which speak only as of the date of this
press release. We undertake no obligation to publicly update or
release any revisions to these forward-looking statements, except
as required by law.
ContactGlobal Public AffairsIntuitive
SurgicalEmail: corp.comm@intusurg.com U.S. Tel: +1
408.523.7337
Intuitive Surgical (NASDAQ:ISRG)
Historical Stock Chart
From Mar 2024 to Apr 2024
Intuitive Surgical (NASDAQ:ISRG)
Historical Stock Chart
From Apr 2023 to Apr 2024